Aboul-Nour Hassan, Jumah Ammar, Mohamed Ghada, Albanna Abdalla Jamal, Alsrouji Owais K, Schultz Lonni, Latack Katie, Miller Joseph, Uddin Khalid, Gunaga Satheesh, Muir Jason, Chebl Alex, Ramadan Ahmad Riad
Departments of Neurology and Neurosurgery, University of Kentucky College of Medicine, Lexington, KY, USA.
Department of Neurosurgery, University of Kentucky College of Medicine, Lexington, KY, USA.
Interv Neuroradiol. 2025 Apr 29:15910199251336948. doi: 10.1177/15910199251336948.
BackgroundIntravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for select stroke patients with acute large vessel occlusion (LVO). Fibrinogen levels may drop after IVT, and a significant decrease in fibrinogen is associated with an increased risk of intracranial hemorrhage (ICH). Our pilot study aimed to explore the relationship between fibrinogen levels and the development of ICH in MT-treated patients and whether bridging with IVT further increases that risk.MethodsThis is a prospective pilot study that enrolled adults presenting with a diagnosis of LVO stroke and eligible to receive MT with or without IVT between April 2020 and May 2023. Fibrinogen levels were drawn before treatment with IVT or MT and immediately following MT.ResultsForty-one patients were enrolled. Median age was 68 years [interquartile range 56-79], 58.5% were females and 56.1% were black. Nineteen patients (46.3%) were treated with MT + IVT, and 22 (53.6%) were treated with MT-only. There was no difference in baseline characteristics between the two groups. Baseline fibrinogen levels were similar between MT + IVT and MT-only groups [391 vs. 352 mg/dL, p = 0.4]. Post MT, the MT + IVT group had lower fibrinogen levels compared to the MT-only group [224 vs. 303 mg/dL, p < 0.001]. Similarly, there was a significant change between baseline and follow-up levels in the MT + IVT vs. MT-only group [106 vs. 39.5 mg/dL, p = 0.001]. Eight patients (19.5%) developed ICH; 5 (26.3%) in the MT + IVT group and 3 (13.6%) in the MT-only group. No significant differences were seen in baseline, follow-up, or change in fibrinogen levels between patients who developed ICH and those who did not. However, when stratified by treatment group, postintervention fibrinogen levels were significantly lower in patients who developed an ICH in the MT + IVT group compared to those without ICH in the MT group (200 vs. 301 mg/dL, p = 0.006). There was also a negative correlation between the change in fibrinogen levels and the rate of first-pass recanalization (Spearman CC -0.33, p = 0.03).ConclusionThis pilot study's preliminary data showed an association between fibrinogen depletion and hemorrhagic transformation in MT-treated patients. Since intracerebral hemorrhage is the most dire side effect in stroke treatment, fibrinogen monitoring in patients undergoing MT after IVT may help identify patients with an increased risk of ICH. Larger, prospective, and multicenter studies are needed to confirm these findings and if fibrinogen repletion should be considered for dysfibrinogenemia.
背景
静脉溶栓(IVT)和机械取栓(MT)是部分急性大血管闭塞(LVO)中风患者的标准治疗方法。IVT后纤维蛋白原水平可能会下降,而纤维蛋白原的显著降低与颅内出血(ICH)风险增加有关。我们的初步研究旨在探讨纤维蛋白原水平与MT治疗患者ICH发生之间的关系,以及IVT桥接治疗是否会进一步增加这种风险。
方法
这是一项前瞻性初步研究,纳入了2020年4月至2023年5月期间诊断为LVO中风且有资格接受MT治疗(无论是否联合IVT)的成年人。在IVT或MT治疗前及MT治疗后立即检测纤维蛋白原水平。
结果
共纳入41例患者。中位年龄为68岁[四分位间距56 - 79岁],58.5%为女性,56.1%为黑人。19例患者(46.3%)接受MT + IVT治疗,22例(53.6%)仅接受MT治疗。两组患者的基线特征无差异。MT + IVT组和仅MT组的基线纤维蛋白原水平相似[391 vs. 352 mg/dL,p = 0.4]。MT治疗后,MT + IVT组的纤维蛋白原水平低于仅MT组[224 vs. 303 mg/dL,p < 0.001]。同样,MT + IVT组与仅MT组的基线水平与随访水平之间也有显著变化[106 vs. 39.5 mg/dL,p = 0.001]。8例患者(19.5%)发生ICH;MT + IVT组5例(26.3%),仅MT组3例(13.6%)。发生ICH的患者与未发生ICH的患者在基线、随访或纤维蛋白原水平变化方面均无显著差异。然而,按治疗组分层时,MT + IVT组发生ICH的患者干预后的纤维蛋白原水平显著低于MT组未发生ICH的患者(200 vs. 301 mg/dL,p = 0.006)。纤维蛋白原水平变化与首次通过再通率之间也存在负相关(Spearman相关系数 -0.33,p = 0.03)。
结论
这项初步研究的初步数据显示,MT治疗患者中纤维蛋白原消耗与出血性转化之间存在关联。由于脑出血是中风治疗中最严重的副作用,对IVT后接受MT治疗的患者进行纤维蛋白原监测可能有助于识别ICH风险增加的患者。需要更大规模、前瞻性和多中心研究来证实这些发现,以及是否应考虑对纤维蛋白原异常血症患者补充纤维蛋白原。